Daniela Choukair, Susanne Rieger, Dirk Bethe, Dorothea Treiber, Georg F Hoffmann, Corinna Grasemann, Peter Burgard, Jörg Beimler, Janna Mittnacht, Burkhard Tönshoff
Resource use and costs of transitioning from pediatric to adult care for patients with chronic kidney disease
Pediatric nephrology (Berlin, Germany)
major histocompatibility complex mhc could serve potential biomarker tumor immunotherapy however yet known whether mhc could distinguish potential beneficiaries singlecell rna sequencing datasets derived patients immunotherapy collected elucidate association mhc immunotherapy response novel mhcsig developed validated using largescale pancancer data including cancer genome atlas immunotherapy cohorts therapeutic value mhcsig explored using 17 crisprcas9 datasets mhcrelated genes associated drug resistance mhcsig significantly positively associated immunotherapy response total mutational burden remarkably mhcsig significantly enriched 6 topranked genes potential therapeutic targets moreover generated hubmhcsig associated survival diseasespecial survival pancancer especially lowgrade glioma result also confirmed cell lines clinical cohort later lowgrade gliomarelated hubmhcsig established regulatory network constructed provided conclusive clinical evidence regarding association mhcsig immunotherapy response developed mhcsig could effectively predict benefits immunotherapy multiple tumors exploration mhcsig revealed potential therapeutic targets regulatory networks